Drug profile

The FDA adverse-event record for Doxorubicin

43 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Doxorubicin. Species, reactions, and outcomes follow.

#1215 of 2,679
by report volume (all drugs)
43
adverse-event reports
23.3%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Doxorubicin ranks #1213 of 2679 by total reports (43). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1213
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Doxorubicin has 43 reports now versus 42 in that prior snapshot: 1 more (2.4%).

Report change
+1
Death-coded reports
+0
Death-coded share
−0.6 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Doxorubicin changes

Signature read: Doxorubicin's 23.3% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
43
Total Reports
10
Deaths Reported
23.3%
Death-coded share of reports

Active Ingredients

Doxorubicin

Administration Routes

UnknownIntravenousOralParenteral

Species Affected

Dog 42
Cat 1

Most Affected Breeds

Retriever - Golden 6
Crossbred Canine/dog 5
Dog (unknown) 4
Retriever - Labrador 4
Beagle 3
Boxer (German Boxer) 2
Spaniel (unspecified) 2
Pit Bull 2
Weimaraner 1
Terrier (unspecified) 1

Most Reported Reactions

Lack of efficacy - NOS 11
Anorexia 10
Diarrhoea 10
Death by euthanasia 9
Weight loss 8
Thrombocytopenia 5
Vomiting 5
Lethargy (see also Central nervous system depression in 'Neurological') 5
Decreased appetite 5
Lethargy (see also Central nervous system depression in Neurological) 5
Neutropenia 4
Urinary incontinence 3

Outcome Breakdown

Outcome Unknown
18 (41.9%)
Ongoing
12 (27.9%)
Euthanized
8 (18.6%)
Recovered/Normal
3 (7.0%)
Died
2 (4.7%)

Doxorubicin: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Doxorubicin (#1215 of 2,679 by report volume); death-coded 23.3%. PlainBreed drug row · death-coded share stamp 23.3% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →